Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • ID: 4051350
  • Report
  • Region: Global
  • 81 Pages
  • GBI Research
1 of 4
Understand the Current Clinical and Commercial Landscape by Considering Disease Pathogenesis, Diagnosis, Prognosis, and the Treatment Strategies Currently Available
National Cancer Institute (NCI) defines Melanoma as a form of cancer that begins in melanocytes (cells that make the pigment melanin) and that may begin in a nevus (mole) (skin melanoma) or in other pigmented tissues, such as the eye or the intestines (NCI, 2014). Melanoma is often considered to be one of the most aggressive and treatment-resistant human cancers, and despite significant advances in melanoma therapy, it remains the deadliest form of skin cancer, with a five-year survival rate of only 15% (Tsao, et al. 2012; Zhang et al., 2015).

Currently, there are a limited number of approved drugs for melanoma, with the most successful by far being Opdivo (nivolumab). This is an immunotherapeutic indicated for the treatment of advanced melanoma - among numerous other oncological indications - and acts to slow tumor growth and metastasis. Approval for the treatment of melanoma was granted in 2014 due to reduced toxicity and an improved response rate compared with other therapeutic options.

Melanoma Therapeutic pipeline is moderately sized, with 579 programs active across all stages of development, but is much larger than the current melanoma market of 130 products. The range of mechanisms of action employed by these compounds is also highly diverse, more so than in the current market landscape.

Melanoma Therapeutic deals landscape is moderately active, with the mean value for co-development deals in 2016 standing at USD304m, which is below the industry average, and the mean value of licensing deals also falling below the industry average, at US$164m, as highlighted. This reflects the low proportion of first-in-class programs involved in deals; the majority of deals involved currently established targets, and there are 176 first-in-class programs not involved in prior deals.

In spite of these developments, there are still significant unmet needs for both cutaneous and extra cutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market.

The report “Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation” provides you to understand current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available. Furthermore, it will help to analyze the melanoma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target and identifies commercial opportunities in the melanoma deals landscape by analyzing trends in licensing and co-development deals and assessing melanoma therapies that are not yet involved in deals, and may be potential investment opportunities.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Unmet Need Remains Despite Significant Advances in Therapy Options
2.2 Moderately Sized but Innovative Pipeline
2.3 Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products

3 The Case for Innovation in the Melanoma Market
3.1 Growing Number of Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Types of Melanoma
4.3 Disease Symptoms
4.3.1 Cutaneous Melanoma
4.3.2 Ocular Melanoma
4.3.3 Mucosal Melanoma
4.3.4 Melanoma of the Internal Organs and Soft Tissue
4.3.5 Advanced Melanoma
4.4 Diagnosis
4.4.1 Cutaneous Melanoma
4.4.2 Ocular Melanoma
4.4.3 Mucosal Melanoma
4.5 Etiology
4.5.1 Phenotypic Characteristics
4.5.2 Exposure to Ultraviolet Radiation
4.5.3 Inherited Genetic Factors
4.5.4 Non-inherited Genetic factors
4.5.5 Xeroderma Pigmentosum
4.5.6 Parkinson’s Disease
4.6 Pathophysiology
4.6.1 Cutaneous Melanoma
4.6.2 Ocular Melanoma
4.6.3 Mucosal Melanoma
4.6.4 Underlying Molecular Pathways
4.7 Epidemiology
4.7.1 Cutaneous Melanoma
4.7.2 Ocular Melanoma
4.7.3 Mucosal Melanoma
4.8 Treatment
4.8.1 Surgery
4.8.2 Radiation Therapy
4.8.3 Pharmacotherapy
4.9 Overview of Marketed Products
4.10 Current Unmet Need in the Melanoma Market

5 Assessment of Pipeline Product Innovation
5.1 Melanoma Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Melanoma Market and Pipeline by Molecular Target
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6 Signaling Network and Innovation Alignment
6.1 Complexity of Signaling Networks in Melanoma
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting Insulin Receptor Substrate 2
7.1.1 Overview of Pipeline Programs Targeting Insulin Receptor Substrate 2
7.2 Pipeline Programs Targeting RAC Serine/Threonine Protein Kinase Alpha, Beta and Gamma
7.2.1 Overview of Pipeline Programs Targeting RAC Serine/Threonine Protein Kinase
7.3 Pipeline Programs Targeting Thrombospondin-1
7.3.1 Overview of Pipeline Programs Targeting Thrombospondin-1
7.4 Pipeline Programs Targeting Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Catalytic Subunit Beta Isoform
7.4.1 Overview of Pipeline Programs Targeting Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform
7.5 Pipeline Programs Targeting e3 Ubiquitin Protein Ligase Mdm2
7.5.1 Overview of Pipeline Programs Targeting e3 Ubiquitin Protein Ligase Mdm2
7.6 Pipeline Programs Targeting Receptor Tyrosine Protein Kinase HER3
7.6.1 Overview of Pipeline Programs Targeting Receptor Tyrosine Protein Kinase HER3
7.7 Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein (NOTCH)1, 2, 3 and 4
7.7.1 Overview of Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1, 2, 3 and 4
7.8 Pipeline Programs Targeting Telomerase Reverse Transcriptase
7.8.1 Overview of Pipeline Programs Targeting Telomerase Reverse Transcriptase
7.9 Conclusion

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Melanoma Deals Landscape
8.3 Licensing Deals
8.3.1 Deals by Region, Deal Value and Year
8.3.2 Deals by stage of development and deal value
8.3.3 Molecule Type
8.3.4 Molecular Target
8.4 Co-development Deals
8.4.1 Deals by region, deal value and year
8.4.2 Deals by Stage of Development and Value
8.4.3 Molecule Type
8.4.4 Molecular Target
8.5 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Research Methodology
9.3.1 Data integrity
9.3.2 Innovative and meaningful analytical techniques and frameworks
9.3.3 Evidence based analysis and insight
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.5 Contact
9.6 Disclaimer

1.1 List of Tables

Table 1:Melanoma Drug Market, Global, Classification of Melanoma, 2016
Table 2: Melanoma Therapeutics Market, Data for IRS2 as a Molecular Target, 2016
Table 3: Melanoma Therapeutics Market, Data for AKT as a Molecular Target, 2016
Table 4: Melanoma Therapeutics Market, Data for THBS1 as a Molecular Target, 2016
Table 5: Melanoma Therapeutics Market, Data for PIK3CB as a Molecular Target, 2016
Table 6: Melanoma Therapeutics Market, Data for MDM2 as a Molecular Target, 2016
Table 7: Melanoma Therapeutics Market, Data for ERBB3 as a Molecular Target, 2016
Table 8: Melanoma Therapeutics Market, Data for NOTCH1, 2, 3 and 4 as Molecular Targets, 2016
Table 9: Melanoma Therapeutics Market, Data for TERT as a Molecular Target, 2016

1.2 List of Figures

Figure 1: Melanoma Drug Market, US, Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2016
Figure 2: Melanoma Drug Market, Global, Sales Performance After Marketing Approval of First-in-Class and Non-First-in-Class Products, 2006-2013 ($m)
Figure 3: Melanoma Drug Market, Global, Marketed Products Overview, 2016
Figure 4: Melanoma Drug Market, Global, Pharmaceutical Pipeline Overview, 2016
Figure 5:Melanoma Drug Market, Global, Pipeline by Stage of Development and Molecule Type, 2016
Figure 6: Melanoma Drug Market, Global, Pipeline by Biologic Sub-class, 2016
Figure 7: Melanoma Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 8: Melanoma Therapeutics Market, Global, Pipeline Breakdown of Cytokine Signaling and Kinase Molecular Target Subcategories, 2016
Figure 9: Melanoma Drug Market, Global, Molecular Target Category Comparison of Pipeline and Marketed Products, 2016
Figure 10: Melanoma Drug Market, Global, Pipeline First-in-Class and Established Molecular Targets by Molecular Target Family, 2016
Figure 11: Melanoma Drug Market, Global, Percentage Distribution of First-in-Class Products in Pipeline by Stage of Development (%), 2016
Figure 12: Melanoma Drug Market, Global, Distribution of First-in-Class Products in Pipeline by Molecular Target (%), 2016
Figure 13: Melanoma Drug Market, Global, All Pipeline Products, 2016 (Part 1)
Figure 14: Melanoma Drug Market, Global, All Pipeline Products, 2016 (Part 2)
Figure 15: Melanoma Drug Market, Global, All Pipeline Products, 2016 (Part 3)
Figure 16: Melanoma Drug Market, Global, All Pipeline Products, 2016 (Part 4)
Figure 17: Melanoma Drug Market, Global, First-in-Class Molecular Target Analysis Matrix, 2016 (Part 1)
Figure 18: Melanoma Drug Market, Global, First-in-Class Molecular Target Analysis Matrix, 2016 (Part 2)
Figure 19: Melanoma Therapeutics Market, Pipeline Programs Targeting IRS2, 2016
Figure 20: Melanoma Therapeutics Market, Pipeline Programs Targeting AKT, 2016
Figure 21: Melanoma Therapeutics Market, Pipeline Programs Targeting THBS1, 2016
Figure 22: Melanoma Therapeutics Market, Pipeline Programs Targeting PIK3CB, 2016
Figure 23: Melanoma Therapeutics Market, Pipeline Programs Targeting MDM2, 2016
Figure 24: Melanoma Therapeutics Market, Pipeline Programs Targeting ERBB3, 2016
Figure 25: Melanoma Therapeutics Market, Pipeline Programs Targeting NOTCH1, 2, 3 and 4, 2016
Figure 26: Melanoma Therapeutics Market, Pipeline Programs Targeting TERT, 2016
Figure 27: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
Figure 28: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
Figure 29: Melanoma Therapeutics Market, Global, Licensing Deals by Region, Value and Year, 2006-2016
Figure 30: Melanoma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 31: Melanoma Therapeutics Market, Global, Licensing Deals by Molecule Type, 2006-2016
Figure 32: Melanoma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2016
Figure 33: Melanoma Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
Figure 34: Melanoma Drug Market, Global, Co-development Deals by Region, Value and Year, 2006-2016
Figure 35: Melanoma Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 36: Melanoma Therapeutics Market, Global, Co-development Deals by Molecule Type, 2006-2016
Figure 37: Melanoma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016
Figure 38: Melanoma Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
Figure 39: Melanoma Therapeutics Market, Global, First-in-Class Programs in Active Development Involved in Previous Deals, 2016 (Part 1)
Figure 40: Melanoma Therapeutics Market, Global, First-in-Class Programs in Active Development Involved in Previous Deals, 2016 (Part 2)
Figure 41: Melanoma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 1)
Figure 42: Melanoma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 2)
Figure 43: Melanoma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 3)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll